WO2014084508A1 - 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 - Google Patents
단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 Download PDFInfo
- Publication number
- WO2014084508A1 WO2014084508A1 PCT/KR2013/009474 KR2013009474W WO2014084508A1 WO 2014084508 A1 WO2014084508 A1 WO 2014084508A1 KR 2013009474 W KR2013009474 W KR 2013009474W WO 2014084508 A1 WO2014084508 A1 WO 2014084508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- protein
- fusion protein
- domain
- aggregation
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01C—AMMONIA; CYANOGEN; COMPOUNDS THEREOF
- C01C1/00—Ammonia; Compounds thereof
- C01C1/16—Halides of ammonium
- C01C1/164—Ammonium chloride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/20—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to a composition for stabilizing a fusion protein of a protein having a physiological activity and an Fc domain, and to a method for stabilizing a fusion protein of a protein and an Fc domain using a composition containing an ammonium salt or an ammonium salt and succinate. It is about.
- Antibody drugs which are used for the treatment of diseases, are biopharmaceuticals with high-level bioprocessing technology such as cell line production technology, cell culture technology, and purification technology.
- a fusion protein (TNFR: Fc etanercept) prepared by fusing an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor to the Fc domain of human IgG1 is used to treat rheumatoid arthritis.
- TNFR Fc etanercept
- Regulatory peptide, 170, 2011 have attempted to increase the half-life in the body by fusing physiologically active substances such as hGH and EPO to the Fc domain (KR10-2008-7018012).
- a substance that binds to the domain has been used as a drug for the treatment of wet macular degeneration (WAMD).
- a fusion protein has a problem in that its structure is large and complex, forming an aggregation caused by physical instability. Factors causing such aggregation exist in various ways during the production and storage of proteins.
- aggregation may occur due to one or more of the following factors.
- pH, salt type, salt concentration, temperature, contact with air, stirring speed, etc. which are not optimal conditions, may be affected, and the concentration condition of the protein may be influenced when formulated.
- the passage of the filter and agitation may affect the buffer exchange, and during storage, temperature change, pH change, contact with air, and agitation may affect the aggregation phenomenon.
- agglomeration may occur when the formulation containing the protein is exposed to light, and the material of the packaging container may also cause agglomeration (Hamada, H. et al., Current Pharmaceutical Biotechnology , 10: 400). , 2009).
- the main cause of the aggregation phenomenon in buffer fusion proteins occurs when the hydrophobic sites of the antibody protein are exposed due to structural changes.
- the aggregation of the hydrophobic sites of the protein molecules to form agglomerates, the coagulation formed in this way may occur in an irreversible form covalent bond between the antibody proteins (Hamada, H. et al., Current Pharmaceutical Biotechnology , 10: 348 , 2009).
- aggregated fusion proteins or antibody proteins generally have reduced activity or lose activity over time.
- these proteins when these proteins are aggregated, they have antigenicity that was not shown in the non-aggregated state, and when injected into the human body, they may cause the production of antibodies (antidrug antibodies, ADA). Therefore, there is an urgent need for a method for reducing such aggregation of fusion proteins and for a stable formulation of fusion proteins with reduced levels of aggregation (Current Trends in Monoclonal Antibody Development and Manufacturing, Biotechnology: Pharmaceutical Aspects Volume XI, 2010, pp 271-291).
- Amphiphilic polymers such as, for example, amino acids (US4362661A, US7648702) such as arginine, lysine, proline, histidine, glycine, polysorbate based surfactants, polyethylene glycols, polyethylene glycols (PEG) or polyvinylpyrrolidone (PVP) Polysaccharides such as dextran, monosaccharides or disaccharides (US5945098A) such as sucrose, maltose and trehalose are used.
- amino acids such as arginine, lysine, proline, histidine, glycine
- PEG polyethylene glycols
- PVP polyvinylpyrrolidone
- Polysaccharides such as dextran, monosaccharides or disaccharides (US5945098A) such as sucrose, maltose and trehalose are used.
- the stability thereof is generally lower than that of the produced antibody protein, so that a tendency to form aggregates is stronger than that of other proteins or antibody proteins.
- a surfactant such as polysorbate
- the present inventors have confirmed that the composition containing ammonium salt or ammonium salt and succinate can increase its stability to facilitate long-term storage by inhibiting aggregation of the protein and the fusion protein of the Fc domain, and the present invention To complete.
- An object of the present invention is to provide a stabilizing composition capable of increasing the stability of a fusion protein by inhibiting aggregation of a protein having a physiological activity and a fusion protein of an Fc domain, and a method for stabilizing an Fc-fusion protein using such a composition. .
- Another object of the present invention to provide a composition for the prevention and treatment of diseases comprising the stabilizing composition.
- the present invention provides a composition for stabilizing the Fc-fusion protein containing the ammonium salt, or ammonium salt and succinate, and a composition for preventing and treating diseases comprising the same.
- the present invention provides a method of stabilizing the fusion protein by adding ammonium salt, or ammonium salt and succinate to the composition containing the Fc-fusion protein.
- FIG. 1 shows Etanercept (fusion protein of the water-soluble portion of the TNF receptor with the Fc domain) of various types of excipients (arginine (Arg), EDTA, glycine (Gly), histidine (His), hydroxypropylcyclodextrin (HP) Cyclodextrin), ammonium chloride, polyethylene glycol (PEG), proline (Pro), sucrose (Sucrose), trehalose (Trehalose), polysorbate 20) stored in a formulation solution containing for 1 week at 50 °C, the aggregation of etanercept This is the result of measuring the degree.
- excipients arginine (Arg), EDTA, glycine (Gly), histidine (His), hydroxypropylcyclodextrin (HP) Cyclodextrin
- Ammonium chloride ammonium chloride
- PEG polyethylene glycol
- Pro proline
- sucrose Sucrose
- Tehalose Tetra
- Figure 2 shows etanercept various excipients (arginine (Arg), proline (Pro), 50 mM ammonium chloride, 100 mM ammonium chloride, 200 mM ammonium chloride, sucrose, polysorbate 20, hydroxypropylcyclodextrin ( HPcD)) is stored in the formulation solution containing for 1 week at 50 °C after measuring the degree of aggregation of etanercept.
- Figure 3 is a result of measuring the degree of aggregation of etanercept after storage of etanercept for 4 weeks at 37 °C in a formulation containing ammonium chloride.
- Arg arginine
- AmCl ammonium chloride
- AmSul ammonium sulfate
- Am + Lys Ammonium Chloride + Lysine
- Am + EDTA Ammonium Chloride + EDTA
- 4 and 5 is a formulation solution containing etanercept for 14 days at 45 °C Arginine, ammonium chloride, ammonium sulfate, ammonium chloride and lysine, ammonium chloride and EDTA, ammonium chloride and polysorbate 20, ammonium chloride and sucrose It is the result of measuring the degree of aggregation of etanercept after storage at.
- AmSul ammonium sulfate
- Am # + Lys ammonium chloride #% + lysine
- FIG. 6 shows etanercept stored at 45 ° C. for 5 days in various buffers including sodium ammonium chloride (Sodium Phosphate, Sodium Succinate, Sodium Citrate, Histidine) It is a result of measuring the aggregation degree of etanercept after.
- sodium ammonium chloride Sodium Phosphate, Sodium Succinate, Sodium Citrate, Histidine
- Figure 7 is a result of measuring the degree of aggregation of etanercept after the composition of etanercept prepared by varying the pH of the succinic acid buffer solution containing ammonium chloride at 45 °C for 5 days.
- AmCl Ammonium Chloride
- AmCl + Lys Ammonium Chloride + Lysine
- fusion protein and protein of the Fc domain refers to a fusion protein in the form of a protein fused to the Fc domain, which is a constant region of the antibody, wherein the protein is the amino acid of several amino acids formed by peptide bonds (peptide)
- polypeptide a polypeptide is used in the same sense as an oligopeptide having a low molecular weight and a protein having a high molecular weight. Therefore, in the present invention, a “fusion protein of a protein and an Fc domain” refers to a “fusion protein of a polypeptide and an Fc domain”. Has the same meaning.
- protein is a protein or polypeptide exhibiting any physiological activity, but the type is not limited, but preferably a soluble portion of various receptors such as TNF-receptor, VEGF receptor, GLP-1 analog (GLP) -1 analog and its derivatives, flt3 ligand, CD40 ligand, erythropoietin, thrombopoietin, thrombopoietin, calcitonin, calcitonin, Fas ligand, ligand for receptor activation of NF-kappa B (RANKL), tumor necrosis Factor (TNF) -related apoptosis inducing ligand (TRAIL), thymus storoma-derived lymphopoietin, granulocyte growth promoting glycoprotein, granulocyte-macrophage growth promoting glycoprotein, mast cell growth factor, stem cell Growth factor, epidermal growth factor, RANTES, growth hormone, insulin, insulin
- the soluble portion of the receptor in the present invention means an extracellular ligand-binding domain of the receptor, or a region including an extracellular ligand-binding portion and an additional transmembrane domain. .
- Fc domain refers to the constant region of the antibody, preferably, but not limited to the Fc domain of human IgG1, IgG2, IgG3 and IgG4 as well as human IgG1 can be used, IgG1, IgG2 , May include some or all of the CH1 domain, CH2 domain, CH3 domain, hinge region of IgG3 and IgG4, and may preferably include a CH2 domain, a CH3 domain and a hinge region except for the CH1 domain. .
- the fusion protein of the protein of the present invention and the Fc domain may be prepared and obtained by a general method used in the art.
- residues other than fusion proteins may be removed through one or more processes selected, such as by centrifugation, ultrafiltration and / or chromatographic procedures.
- the present invention provides a composition for stabilizing a fusion protein of a protein and an Fc domain containing an ammonium salt.
- ammonium salt refers to a salt formed by combining ammonia and an acid, and may be represented by the general formula NH 4 X (X is a monovalent acid group).
- X is a monovalent acid group.
- ammonium chloride, ammonium sulfate, ammonium carbonate and ammonium nitrate may be used, but is not limited thereto.
- the ammonium salt may be used at a concentration of 5 to 500 mM selected from ammonium chloride, ammonium sulfate, ammonium carbonate and ammonium nitrate.
- an ammonium salt having a concentration of 12.5 to 200 mM was used, but even when a small amount of ammonium salt of 12.5 mM or less or an ammonium salt of 200 mM or more is used, there is an effect of inhibiting aggregation of the fusion protein.
- the ammonium salts of the present invention effectively inhibit aggregation of fusion proteins of polypeptides and Fc domains.
- the extracellular ligand binding portion of the human p75 tumor necrosis factor receptor is stored in an ammonium chloride or ammonium sulfate solution when the fusion protein is fused to the Fc domain of human IgG1, the fusion protein is not stored in the ammonium salt solution. Compared to that, the degree of aggregation was reduced by about 80% (Fig. 1, Fig. 2).
- the composition for stabilizing the fusion protein of the protein and the Fc domain according to the present invention may further include a succinate, the succinate contains a fusion protein of the protein and the Fc domain of the present invention
- a succinate contains a fusion protein of the protein and the Fc domain of the present invention
- the succinate is added to a concentration of 5 to 200 mM, more preferably 20 to 30 mM, as well as sodium succinate, various succinates known in the art can be used.
- the succinate buffer is adjusted to have a pH of 5.5 to 6.5, more preferably to pH 6.0 to 6.3. When the pH is less than or equal to 5.5 or more than 6.5, aggregation of the fusion protein is increased, and thus, it is preferable that the pH is within the above range.
- sodium phosphate, sodium succinate, sodium citrate, and histidine buffers are additionally added to ammonium chloride excipients that have been shown to suppress aggregation of fusion proteins.
- the formulation using sodium succinic acid as a buffer was significantly lower than the formulation using sodium phosphate as a buffer currently used in the commercial etanercept (trade name Enbrel) at pH 6.5. It was confirmed. In addition, it was confirmed that the formulation with sodium succinate exhibited better aggregation inhibition than the formulation with other buffers at pH 6.0 (FIG. 6).
- amino acids are known as substances which inhibit the aggregation of proteins, and among them, basic amino acids are excellent in role as anti-aggregation agents.
- arginine is used as an anticoagulant (US 7648702 B2)
- a formulation for stabilizing Fc modified antibodies with a combination of lysine, arginine, histidine and sugar, acid buffer and polysorbate US 20100254985 Patents have been reported.
- anionic buffers such as sugars such as trehalose, sucrose, mannitol, maltose, phosphate, and citrate.
- the surfactant is attached to the denatured and exposed hydrophobic sites of the protein to increase the solubility to prevent aggregation, typically polysorbate Muromonab, Abciximab, Rituximab, Daclizimab, Alemtuzumab, Adalimumab, Bevacizumab, Natalizumab, etc. Is used in the formulation of antibody proteins.
- At least one excipient selected from basic amino acids, sugars and surfactants may be additionally used in the composition for stabilizing the fusion protein of the protein and the Fc domain according to the present invention. have.
- arginine, lysine, histidine and the like may be used at a concentration of 1 to 50 mM, and as sugar, sucrose, trehalose, mannitol, maltose and the like at a concentration of 0.5 to 10% w / v,
- surfactant Triton, Tween, and Pluronic substances may be used at a concentration of 0.001 to 0.1% w / v, but are not limited thereto. Excipients that can be used in the art to inhibit can be used without limitation.
- the present invention provides a method of stabilizing a fusion protein of a protein and an Fc domain by adding an ammonium salt to a composition containing a fusion protein of a protein and an Fc domain, the composition further comprising succinate.
- the succinate may be added at a concentration of 5 to 200 mM in the form of a buffer of pH 5.5 to 6.5.
- the ethanercept and the protein which are commercially available arthritis therapeutics, were expressed in CHO cells, and then purified by high purity.
- the ammonium salt according to the present invention is effective in inhibiting the aggregation of the fusion protein and stabilizing the formulation thereof.
- the use of the ammonium salt according to the present invention in comparison with arginine used for preventing aggregation of etanercept products In this case, it was confirmed that the aggregation inhibitory effect of the fusion protein is more excellent (Example 2).
- the present invention provides a composition for treating arthritis, containing a fusion protein and an ammonium salt in which the extracellular ligand binding portion of the human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG1.
- TNFR Fc
- Fc formulation means a formulation containing etanercept protein
- This experiment was performed to compare the effects of excipients that inhibit aggregation of TNFR: Fc. Specifically, the experiment is to determine whether the difference in the aggregation phenomenon of TNFR: Fc stored at 50 °C according to the type of excipient. Except for arginine, an aqueous solution prepared by the same formulation as used in Amgen's Enbrel product was added and each excipient was added (final concentration was 25 mg / ml Etanercept, 0.66% w / v sucrose, 65 mM sodium chloride, 17 mM sodium phosphate, hydrogen ion concentration 6.4) The degree of aggregation after storage at 50 °C was compared.
- the final concentration of excipient used in each aqueous solution was 25 mM arginine, 100 mM proline, 80 mM histidine, 100 mM glycine, 0.2 M ammonium chloride, 10 mM EDTA, 20% w / v sucrose, 20% w / v trihalose , 10% w / v polyethylene glycol, 0.04% w / v polysorbate 20, 0.1% w / v hydroxypropylcyclodextrin, and the degree of aggregation of TNFR: Fc was measured using SEC-HPLC.
- Protein was injected into TSK-gel G3000SWXL (7.8 X 300 mm) HPLC column (TOSOH, Japan) under buffer mobile phase conditions of 50 mM sodium phosphate (pH 6.8), 0.15 M sodium chloride, 0.05% w / v sodium azide and 280 Protein peaks were detected at nm.
- polysorbate 20 as a surfactant component, hydroxypropylcyclodextrin, amphiphilic polymer polyethylene glycol, EDTA as a metal ion removing agent, arginine as an amino acid-based excipient, proline, histidine, glycine and the like do not inhibit aggregation at all.
- sucrose and trihalose which are sugar-based excipients, had better anti-agglomeration effects than other excipients.
- almost all TNFR: Fc was aggregated, whereas only about 50% of the protein was changed to the aggregated form when ammonium chloride was used as the excipient.
- this experiment was performed using TNFR: Fc. This experiment was performed to compare the degree of aggregation when arginine, an excipient used to inhibit aggregation of TNFR: Fc, and other excipients were used.
- Excipients selected for comparison are proline, ammonium chloride, sucrose, polysorbate 20 and hydroxypropylcyclodextrin.
- a negative control except for arginine at a final concentration of 10 mg / ml TNFR: Fc, 1% w / v sucrose, 100 mM sodium chloride, 25 mM sodium phosphate, hydrogen ion concentration of 6.4, and a positive control containing 25 mM arginine were prepared.
- the excipients were replaced with 100 mM proline, 50-200 mM ammonium chloride, 20% w / v sucrose, 0.04% w / v polysorbate 20, and 0.1% w / v hydroxypropylcyclodextrin, respectively. Each was tested. Each formulation was stored at 50 ° C. for 1 week in the same manner as in Example 1. SEC-HPLC was used in the same manner as in Example 1 to determine the aggregation phenomenon.
- the experiment was performed by modifying the experiment temperature to 37 °C in order to further demonstrate the aggregation inhibitory effect of the ammonium chloride excipient proved to be effective at high temperature.
- This experiment was carried out to demonstrate the effect of inhibiting aggregation by the combination of ammonium sulfate, an ammonium salt other than ammonium chloride, with other excipients generally known to be capable of inhibiting protein aggregation.
- the final concentration was 4 weeks at 37 ° C.
- Stabilizing buffer composition without excipients for suppressing aggregation negative control
- formulation with 25 mM arginine positive control
- Formulations containing lysine were used. Each formulation was stored at 37 ° C. for 4 weeks. The aggregation inhibitory effect was observed using SEC-HPLC as in Example 1.
- TNFR Fc in combination with ammonium chloride and ammonium sulfate, and other excipients generally known to have protein aggregation inhibitory effects.
- Agglutination inhibitory effects of ammonium salts were observed in formulation solutions of 50 mg / ml TNFR: Fc stored at 45 ° C. under 1% w / v sucrose, 100 mM sodium chloride, 25 mM sodium phosphate, and stabilization buffer at pH 6.4. It was.
- Stabilization buffer composition without agglutination inhibitor negative control
- formulation containing arginine at a final concentration of 25 mM positive control
- formulation containing 12.5 mM, 25 mM, 50 mM respectively, at a final concentration of ammonium chloride
- 25 Formulations containing mM ammonium sulfate, 25 mM ammonium chloride and 25 mM lysine or 5% w / v sucrose formulations containing 50 mM ammonium chloride and 25 mM lysine or 5% w / v sucrose
- the aggregation inhibitory effect was observed using SEC-HPLC as in Example 1.
- composition containing ammonium salts or ammonium salts and succinate salts according to the present invention effectively inhibits the aggregation of Fc-fusion proteins, and thus enables long-term storage of the fusion proteins, and thus are widely used in the medical field using Fc-fusion proteins. Can be used.
Abstract
Description
% Aggregation | ||||
Week | 0 | 1 | 2 | 4 |
Control | 0.3 | 1.3 | 1.4 | 3.1 |
Arg | 1.1 | 1.4 | 3.1 | |
AmCl | 1.1 | 13.3 | 2.7 | |
AmSul | 1.0 | 1.3 | 2.7 | |
Am+Lys | 0.9 | 1.3 | 2.4 | |
Am+EDTA | 1.6 | 2.8 | 5.2 | |
Am+Tween | 1.6 | 2.7 | 4.9 | |
Am+Sucrose | 1.0 | 1.2 | 2.4 |
% Aggregation | ||||
Day | 0 | 3 | 7 | 14 |
Control | 0.9 | 2.2 | 3.7 | 4.6 |
Arg | 1.9 | 3.2 | 3.8 | |
AmCl 12.5 | 2.3 | 3.5 | 4.4 | |
AmCl 25 | 2.1 | 3.2 | 4.0 | |
AmCl 50 | 1.8 | 3.0 | 3.7 | |
AmSul | 1.7 | 3.0 | 3.6 | |
Am25+Lys | 1.7 | 2.8 | 3.5 | |
Am25+Suc | 1.6 | 2.9 | 3.5 | |
Am50+Lys | 1.5 | 2.6 | 3.0 | |
Am50+Suc | 1.8 | 2.6 | 3.1 |
Claims (32)
- 암모늄염을 함유하는, 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 숙신산염(succinate)를 추가로 포함하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제2항에 있어서, 상기 숙신산염은 5 내지 200 mM 농도로 포함되는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제2항 또는 제3항에 있어서, 숙신산염은 pH는 5.5 내지 6.5의 완충액 역할을 수행하는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 암모늄염은 단백질과 Fc 도메인의 융합 단백질의 응집을 억제하는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 암모늄염은 염화암모늄, 황산암모늄, 탄산암모늄 및 질산암모늄 중에서 선택되는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 암모늄염은 5 내지 500 mM의 농도로 함유되는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 융합 단백질은 인간 p75 종양괴사인자 수용체의 세포외 리간드 결합부가 인간 IgG1의 Fc 도메인에 융합된 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 안정화용 조성물은 부형제를 추가로 함유하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제9항에 있어서, 상기 부형제는 염기성 아미노산, 당 및 계면활성제 중에서 선택되는 1종 이상인 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제9항에 있어서, 상기 부형제는 수크로오스 또는 라이신, 또는 둘 다 인것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 단백질과 Fc 도메인의 융합 단백질을 함유하는 조성물에 암모늄염을 가하여 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 조성물은 숙신산염을 추가로 포함하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제13항에 있어서, 상기 숙신산염은 5 내지 200 mM 농도로 포함되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제13항 또는 제14항에 있어서, 숙신산염은 pH는 5.5 내지 6.5의 완충액 형태로 첨가되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 암모늄염은 단백질과 Fc 도메인의 융합 단백질의 응집을 억제하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 암모늄염은 염화암모늄, 황산암모늄, 탄산암모늄 및 질산암모늄 중에서 선택되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 암모늄염은 5 내지 500 mM의 농도로 함유되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 융합 단백질은 인간 p75 종양괴사인자 수용체의 세포외 리간드 결합부가 인간 IgG1의 Fc 도메인에 융합된 것인 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 안정화용 조성물은 부형제를 추가로 함유하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제20항에 있어서, 상기 부형제는 염기성 아미노산, 당 및 계면활성제 중에서 선택되는 1종 이상인 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제21항에 있어서, 상기 부형제는 수크로오스 또는 라이신, 또는 둘 다 인것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 인간 p75 종양괴사인자 수용체의 세포외 리간드 결합부가 인간 IgG1의 Fc 도메인에 융합된 융합 단백질과 암모늄염을 함유하는 관절염 치료용 조성물.
- 제23항에 있어서, 숙신산염을 추가로 포함하는 것을 특징으로 하는 관절염 치료용 조성물.
- 제24항에 있어서, 상기 숙신산염은 5 내지 200 mM 농도로 포함되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제24항 또는 제25항에 있어서, 숙신산염은 pH는 5.5 내지 6.5의 완충액 형태로 첨가되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 암모늄염은 단백질과 Fc 도메인의 융합 단백질의 응집을 억제하는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 암모늄염은 염화암모늄, 황산암모늄, 탄산암모늄 및 질산암모늄 중에서 선택되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 암모늄염은 5 내지 500 mM의 농도로 함유되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 조성물은 부형제를 추가로 함유하는 것을 특징으로 하는 관절염 치료용 조성물.
- 제30항에 있어서, 상기 부형제는 염기성 아미노산, 당 및 계면활성제 중에서 선택되는 1종 이상인 것을 특징으로 하는 관절염 치료용 조성물.
- 제30항에 있어서, 상기 부형제는 수크로오스 또는 라이신, 또는 둘 다 인것을 특징으로 하는 관절염 치료용 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015542943A JP6026002B2 (ja) | 2012-11-27 | 2013-10-23 | タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物 |
CN201380065765.7A CN104870019A (zh) | 2012-11-27 | 2013-10-23 | 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物 |
US14/439,644 US9474803B2 (en) | 2012-11-27 | 2013-10-23 | Composition for stabilizing fusion protein in which protein and FC domain are fused |
EP13857947.9A EP2926834A4 (en) | 2012-11-27 | 2013-10-23 | COMPOSITION FOR STABILIZING A FUSION PROTEIN IN WHICH A PROTEIN AND A DOMAIN FC ARE MERGED |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0134946 | 2012-11-27 | ||
KR20120134946 | 2012-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014084508A1 true WO2014084508A1 (ko) | 2014-06-05 |
Family
ID=50828096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/009474 WO2014084508A1 (ko) | 2012-11-27 | 2013-10-23 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9474803B2 (ko) |
EP (1) | EP2926834A4 (ko) |
JP (1) | JP6026002B2 (ko) |
KR (1) | KR101419884B1 (ko) |
CN (1) | CN104870019A (ko) |
WO (1) | WO2014084508A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
US10279048B2 (en) | 2016-07-13 | 2019-05-07 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
KR102413592B1 (ko) * | 2016-10-21 | 2022-06-27 | 암젠 인크 | 약학적 제형 및 그의 제조 방법 |
KR20180046888A (ko) | 2016-10-28 | 2018-05-09 | (주)셀트리온 | 안정한 약제학적 제제 |
WO2019036619A1 (en) * | 2017-08-18 | 2019-02-21 | Reform Biologics, Llc | STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN |
EP3679945A4 (en) * | 2017-09-07 | 2021-06-16 | JCR Pharmaceuticals Co., Ltd. | AQUEOUS PHARMACEUTICAL COMPOSITION |
JP7183268B2 (ja) * | 2017-11-20 | 2022-12-05 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用 |
GB201901547D0 (en) * | 2019-02-05 | 2019-03-27 | Arecor Ltd | Stabilized Fc Fusion protein solutions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
US7648702B2 (en) | 2002-02-27 | 2010-01-19 | Immunex Corporation | Stable aqueous formulation of a soluble TNF receptor and arginine |
US20100254985A1 (en) | 2006-02-03 | 2010-10-07 | Medimmune, Llc | Protein Formulations |
US20120116057A1 (en) * | 2009-07-08 | 2012-05-10 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
WO2012143418A1 (en) * | 2011-04-20 | 2012-10-26 | Sandoz Ag | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc |
WO2013006454A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
US5464934A (en) | 1993-05-14 | 1995-11-07 | Mallinckrodt Medical, Inc. | Metal chelates as spacer compounds in biologically active peptides |
CA2423227C (en) * | 2000-10-12 | 2011-11-29 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
IL159475A0 (en) | 2001-06-21 | 2004-06-01 | Altus Biologics Inc | Spherical protein particles, compositions containing the same and methods for the production thereof |
MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
CN100509847C (zh) | 2003-08-01 | 2009-07-08 | 安美基公司 | 结晶肿瘤坏死因子受体2多肽 |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
ES2678060T3 (es) | 2006-12-01 | 2018-08-08 | E. R. Squibb & Sons, L.L.C. | Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos |
EP2162472B1 (en) | 2007-05-30 | 2013-02-27 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
AU2008314689A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
EP2403874A1 (en) | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
RU2600847C2 (ru) * | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
-
2013
- 2013-10-23 WO PCT/KR2013/009474 patent/WO2014084508A1/ko active Application Filing
- 2013-10-23 US US14/439,644 patent/US9474803B2/en active Active
- 2013-10-23 CN CN201380065765.7A patent/CN104870019A/zh active Pending
- 2013-10-23 EP EP13857947.9A patent/EP2926834A4/en not_active Withdrawn
- 2013-10-23 JP JP2015542943A patent/JP6026002B2/ja not_active Expired - Fee Related
- 2013-10-23 KR KR1020130126295A patent/KR101419884B1/ko active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
US7648702B2 (en) | 2002-02-27 | 2010-01-19 | Immunex Corporation | Stable aqueous formulation of a soluble TNF receptor and arginine |
US20100254985A1 (en) | 2006-02-03 | 2010-10-07 | Medimmune, Llc | Protein Formulations |
US20120116057A1 (en) * | 2009-07-08 | 2012-05-10 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
WO2012143418A1 (en) * | 2011-04-20 | 2012-10-26 | Sandoz Ag | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc |
WO2013006454A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Non-Patent Citations (7)
Title |
---|
"Current Trends in Monoclonal Antibody Development and Manufacturing", BIOTECHNOLOGY: PHARMACEUTICAL ASPECTS, vol. XI, 2010, pages 271 - 291 |
CHUNG, H.S. ET AL., REGULATORY PEPTIDE, vol. 170, 2011 |
HAMADA, H. ET AL., CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol. 10, 2009, pages 348 |
HAMADA, H. ET AL., CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol. 10, 2009, pages 400 |
KUNZ, W. ET AL., CURR. OPIN. COLL. INTERFACE SCI., vol. 9, 2004, pages 1937 |
See also references of EP2926834A4 * |
STEVEN J. SHIRE ET AL.: "Biotechnology: Pharmaceutical Aspects", CURRENT TRENDS IN MONOCLONAL ANTIBODY DEVELOPMENT AND MANUFACTURING, vol. XI, 2010, pages 115 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
Also Published As
Publication number | Publication date |
---|---|
US20150313996A1 (en) | 2015-11-05 |
JP6026002B2 (ja) | 2016-11-16 |
KR20140067897A (ko) | 2014-06-05 |
EP2926834A4 (en) | 2016-04-20 |
US9474803B2 (en) | 2016-10-25 |
CN104870019A (zh) | 2015-08-26 |
EP2926834A1 (en) | 2015-10-07 |
KR101419884B1 (ko) | 2014-07-16 |
JP2016502528A (ja) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014084508A1 (ko) | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 | |
US9453067B2 (en) | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc | |
EP2568960B1 (en) | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin | |
CA2476934C (en) | Stabilized tnfr-fc composition comprising arginine | |
KR102061355B1 (ko) | 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법 | |
KR101335765B1 (ko) | 지속형 에리스로포이에틴 결합체의 액상 제제 | |
EP2714009A1 (en) | Stable liquid formulation of etanercept | |
WO2011090305A2 (en) | Liquid formulations for long-acting g-csf conjugate | |
TW201410704A (zh) | 長效胰島素及胰促泌素肽之液體製劑 | |
WO2020055123A1 (ko) | 단백질을 포함하는 액상 조성물 | |
US20220323587A1 (en) | Dissolvable films and methods of their use | |
JP7442595B2 (ja) | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 | |
WO2018131893A1 (ko) | 안정한 액체 제제 | |
WO2024087834A1 (zh) | 生长激素fc融合蛋白注射液及其用途 | |
WO2017116191A2 (ko) | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 | |
WO2018080196A2 (ko) | 안정한 약제학적 제제 | |
JP2024503299A (ja) | 可溶性gp130二量体を含む製剤と使用方法 | |
NZ620160B2 (en) | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13857947 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14439644 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015542943 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013857947 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |